Hydra Biosciences - Top 20 VC deals of 2008

Hydra Biosciences, Fiercebiotech's top venture capital deals of 2008Company: Hydra Biosciences
Based: Cambridge, MA
Amount: $39.22

Investors: Abingworth Management, BioVentures Investors, New Enterprise Associates, Biogen Idec New Ventures, Lilly Ventures, MedImmune Ventures, Polaris Venture Partners, Advanced Technology Ventures

Scoop: Cambridge's Hydra raised $39.22 million in two rounds of finacing in 2008. The company is developing drugs to treat pain, inflammation, cardiovascular and other diseases using ion channels. Hydra's funding is being used to advance Transient Receptor Potential ion channel drug programs; its most advanced program will be moving toward clinical trials in 2009. The company has already secured an additional $22 million in 2009.

Hydra Biosciences - Top 20 VC deals of 2008

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i